|Videos|August 30, 2021

Dr. Zhang on risk stratification and treatment selection in mCSPC

Risk factors Dr.Zhang highlights include site of metastases, PSA response, and metastases burden.

Jingsong Zhang, MD, PhD, discusses contributing factors to risk stratification and subsequent treatment selection in patients with metastatic castration-sensitive prostate cancer. The factors Zhang highlights include site of metastases, PSA response, and metastases burden.

Zhang is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more